GlassScriptPhysician profile
Mark A Wyant
NPI 1558456632
$5,497.39
in general payments reported to CMS, 2019-2025
46 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $1,145 · 2021: $2,328 · 2022: $116 · 2023: $248 · 2024: $487 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,148.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $686.68 | 2019-2021 | |
| Pfizer INC. | $469.16 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $358.34 | 2019-2021 | |
| Abbvie INC. | $321.62 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $313.94 | 2019-2021 | |
| Dexcom, INC. | $274.88 | 2024-2025 | Dexcom G6 Transmitter |
| Genzyme Corporation | $265.76 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.17 | 2019-2021 | |
| Abbott Laboratories | $256.09 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $208.81 | 2019-2025 | Capvaxive, Gardasil 9 |
| Amgen INC. | $186.47 | 2019-2021 | |
| Glaxosmithkline, LLC. | $180.42 | 2020-2025 | Rotarix, Bexsero, Pediarix |
| Teva Pharmaceuticals USA, INC. | $154.11 | 2019-2021 | |
| Medtronic, INC. | $134.62 | 2021-2025 | Intellis Adaptivestim |
| Takeda Pharmaceuticals U.S.A., INC. | $127.26 | 2020-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wyant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.